---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-324463"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T10:43:33.515203+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO closes $370M upfront eye care collaboration with AbbVie for RGX-314 gene therapy

## Summary
- Upfront payment of $370M; potential for up to $1.38B in development, regulatory, and commercial milestones.
- REGENXBIO and AbbVie to share equally in US profits; AbbVie to pay tiered royalties on ex-US net sales.
- REGENXBIO responsible for ongoing trials; AbbVie leads global clinical development and commercialization.
- REGENXBIO to lead manufacturing for clinical and US commercial supply; AbbVie for ex-US commercial supply.
- Agreement covers RGX-314 for wet AMD, diabetic retinopathy, and other chronic retinal diseases.

## SEC filing metadata
- accession: 0001193125-21-324463
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000119312521324463/0001193125-21-324463-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000119312521324463/d257796d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-324463
- JSON: https://secwatch.observer/filing/0001193125-21-324463.json
- Plain text: https://secwatch.observer/filing/0001193125-21-324463.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.